A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Arlocabtagene autoleucel (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
Indications Multiple myeloma
Focus Adverse reactions; First in man
Sponsors Juno Therapeutics

19 Nov 2024 According to a Bristol Myers Squibb media release, results from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California.
24 Jan 2024 Status changed from recruiting to active, no longer recruiting.
12 Dec 2023 Results (As of May 24, 2023, n=70 ) of updated safety and efficacy, presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com